COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a population-based case-control study in St. Petersburg, Russia

Anton Barchuk; Anna Bulina; Mikhail Cherkashin; Natalia Berezina; Tatyana Rakova; Darya Kuplevatskaya; Oksana Stanevich; Dmitriy Skougarevskiy; Artemiy Okhotin

doi:10.1101/2022.01.24.22269714

Article Information

doi

https://doi.org/10.1101/2022.01.24.22269714

History

May 2, 2022.

Article Versions

Version 1 (January 24, 2022 - 22:30).
You are viewing Version 2, the most recent version of this article.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Anton Barchuk1,5,6,✉,
Anna Bulina1,
Mikhail Cherkashin2,
Natalia Berezina2,
Tatyana Rakova2,
Darya Kuplevatskaya2,
Oksana Stanevich1,4,
Dmitriy Skougarevskiy1 and
Artemiy Okhotin3,4

¹Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
²Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
³Tarusa Hospital, Karla Libknekhta Ulitsa 16, Tarusa, Russia, 249100
⁴ITMO University, St. Petersburg, Russia, 197101
⁵NN Petrov National Research Medical Centre of Oncology, Pesochny, Leningradskaya Ulitsa 68, St. Petersburg, Russia, 197758
⁶Health Sciences, Faculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, Tampere, Finland, 33520